SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane
Hui Li(University of Maryland, Baltimore), Haihe Wang(Guizhou Normal University)
Cited by 40
Related Papers
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer
|Nature Medicine|2018|83
Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer
|Cancer Immunology Immunotherapy|2020|71
Independent oncogenic and therapeutic significance of phosphatase PRL‐3 in FLT3‐ITD–negative acute myeloid leukemia
|Cancer|2014|43
Inhibition of stromal MAOA leading activation of WNT5A enhance prostate cancer immunotherapy by involving the transition of cancer-associated fibroblasts
|Journal for ImmunoTherapy of Cancer|2025|13
Integrative analysis of multi-omics data reveals inhibition of RB1 signaling promotes apatinib resistance of hepatocellular carcinoma
|International Journal of Biological Sciences|2023|6